OncoMatch/Clinical Trials/NCT06351631
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Is NCT06351631 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Bomedemstat for thrombocythemia, essential.
Treatment: Bomedemstat — The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic remission. No hypothesis testing will be conducted in this study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myeloproliferative Neoplasm
Prior therapy
Must have received: bomedemstat (bomedemstat)
Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator
Must have received: bomedemstat (bomedemstat)
ET and PV participants from established feeder studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic remission, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Michigan ( Site 6000) · Ann Arbor, Michigan
- DUHS Duke Blood Cancer Center ( Site 6005) · Durham, North Carolina
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007) · Columbus, Ohio
- UPMC Hillman Cancer Center ( Site 6004) · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify